Shares of Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price target of $7.00 for the company and are anticipating that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Ohr Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to related companies.
Several research firms have commented on OHRP. ValuEngine downgraded Ohr Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Roth Capital downgraded Ohr Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $7.00 price objective on the stock. in a report on Friday. Finally, Zacks Investment Research downgraded Ohr Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th.
Ohr Pharmaceuticals (OHRP) opened at $0.38 on Friday. The company has a market capitalization of $3.95, a price-to-earnings ratio of -0.64 and a beta of 0.48. Ohr Pharmaceuticals has a fifty-two week low of $0.35 and a fifty-two week high of $2.18.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/06/zacks-ohr-pharmaceuticals-inc-ohrp-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.